Figure 8. Combined prognostic significance of MMP14 and PKM2 in patients with pancreatic cancer. (A) Spearman correlation of MMP14 and PKM2 expression levels in GSE71729, GSE78229 and TCGA datasets. (B) Multivariate cox regression was used to test the prognostic significance of KRAS, TP53, CDKN2A and SMAD4 alterations and MMP14 and PKM2 expression in patients with pancreatic cancer in TCGA datasets. The log-rank test was used to determine the overall survival P-value. (C) Kaplan-Meier plotters demonstrated the different overall survival of pancreatic cancer patients with high expression levels of MMP14 and PKM2 and pancreatic cancer patients with low expression levels of MMP14 and PKM2 in TCGA dataset. Log-rank test was used to determine the P values.